The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells
Machiko Kojima(The University of Tokyo), Tomoyuki Fujii(The University of Tokyo)
Cited by 31
Related Papers
Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer
|Oncotarget|2017|67
Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
|BMC Cancer|2014|63
Antitumor Activity and Induction of TP53-Dependent Apoptosis toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423
|PLoS ONE|2014|51
Putative tumor suppression function of SIRT6 in endometrial cancer
|FEBS Letters|2015|36